Search Result

Results for "

vegfs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (6) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (4) Apoptosis (14) Aryl Hydrocarbon Receptor (1) Aurora Kinase (2) Autophagy (3) Bacterial (3) Bcl-2 Family (1) Beclin1 (2) Caspase (1) CDK (2) Complement System (3) COX (5) Dihydroorotate Dehydrogenase (1) DNA/RNA Synthesis (2) Drug Metabolite (1) EBI2/GPR183 (1) EGFR (1) Endogenous Metabolite (3) ERK (4) Estrogen Receptor/ERR (1) FAK (1) FGFR (2) FXR (1) GSK-3 (1) HCV (1) HIF/HIF Prolyl-Hydroxylase (14) Histamine Receptor (6) HSP (1) HSV (1) Integrin (4) Interleukin Related (2) Isotope-Labeled Compounds (2) JAK (1) JNK (3) Leukotriene Receptor (1) Macrophage migration inhibitory factor (MIF) (1) MAP3K (1) MDM-2/p53 (2) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) MMP (4) Monoamine Oxidase (1) mTOR (2) NADPH Oxidase (1) NF-κB (5) Notch (1) p38 MAPK (2) Parasite (2) PD-1/PD-L1 (1) PDGFR (3) PERK (1) PI3K (1) Pim (1) PKC (1) PKD (1) PPAR (1) Raf (1) Reactive Oxygen Species (2) SARS-CoV (2) Small Interfering RNA (siRNA) (2) Src (1) SRPK (2) STAT (2) TAM Receptor (1) TGF-β Receptor (1) Thrombin (1) Tie (1) Tyrosinase (1) VEGFR (65)
By Research Areas:	Cancer (80) Cardiovascular Disease (27) Endocrinology (5) Infection (7) Inflammation/Immunology (22) Metabolic Disease (7) Neurological Disease (1)

By Targets:

Akt (6)

Angiotensin-converting Enzyme (ACE) (1)

Antibiotic (4)

Apoptosis (14)

Aryl Hydrocarbon Receptor (1)

Aurora Kinase (2)

Autophagy (3)

Bacterial (3)

Bcl-2 Family (1)

Beclin1 (2)

Caspase (1)

CDK (2)

Complement System (3)

COX (5)

Dihydroorotate Dehydrogenase (1)

DNA/RNA Synthesis (2)

Drug Metabolite (1)

EBI2/GPR183 (1)

EGFR (1)

Endogenous Metabolite (3)

ERK (4)

Estrogen Receptor/ERR (1)

FAK (1)

FGFR (2)

FXR (1)

GSK-3 (1)

HCV (1)

HIF/HIF Prolyl-Hydroxylase (14)

Histamine Receptor (6)

HSP (1)

HSV (1)

Integrin (4)

Interleukin Related (2)

Isotope-Labeled Compounds (2)

JAK (1)

JNK (3)

Leukotriene Receptor (1)

Macrophage migration inhibitory factor (MIF) (1)

MAP3K (1)

MDM-2/p53 (2)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

MMP (4)

Monoamine Oxidase (1)

mTOR (2)

NADPH Oxidase (1)

NF-κB (5)

Notch (1)

p38 MAPK (2)

Parasite (2)

PD-1/PD-L1 (1)

PDGFR (3)

PERK (1)

PI3K (1)

Pim (1)

PKC (1)

PKD (1)

PPAR (1)

Raf (1)

Reactive Oxygen Species (2)

SARS-CoV (2)

Small Interfering RNA (siRNA) (2)

Src (1)

SRPK (2)

STAT (2)

TAM Receptor (1)

TGF-β Receptor (1)

Thrombin (1)

Tie (1)

Tyrosinase (1)

VEGFR (65)

By Research Areas:

Cancer (80)

Cardiovascular Disease (27)

Endocrinology (5)

Infection (7)

Inflammation/Immunology (22)

Metabolic Disease (7)

Neurological Disease (1)

121

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P5558

KLTWQELYQLKYKGI	VEGFR	Inflammation/Immunology
KLTWQELYQLKYKGI (QK) is a VEGF mimicking peptide, binds to the VEGF receptors and competes with VEGF. KLTWQELYQLKYKGI is active in gastric ulcer healing in rodents when administered either orally or systemically. KLTWQELYQLKYKGI shows the ability to induce capillary formation and organization in vitro .

HY-109561

Pegaptanib sodium EYE001; NX1838	VEGFR	Metabolic Disease Inflammation/Immunology
Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .

HY-108868

Mersalyl Salirgan; Salurin; Salyrgan	HIF/HIF Prolyl-Hydroxylase VEGFR	Metabolic Disease
Mersalyl (Salirgan) is a potent vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1 (HIF-1) inducer. Mersalyl induces VEGF and ENO1 mRNA expression. Mersalyl shows diuresis effects .

HY-18185

JNJ 17029259	VEGFR	Cancer
JNJ 17029259 is an orally active and selective *VEGF-R2* kinase inhibitor. JNJ 17029259 inhibits VEGF-mediated signal transduction. JNJ 17029259 has anti-angiogenic activity .

HY-N7177

Hydroxytanshinone IIA	Drug Metabolite VEGFR	Cancer
Hydroxytanshinone IIA is a hydroxylated metabolite of Tanshinone IIA. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2* .

HY-P9906A

Bevacizumab (PBS) Maximum Cited Publications 23 Publications Verification Anti-Human VEGF, Humanized Antibody (PBS)	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all *VEGF-A* isoforms with high affinity .

HY-P5107

Protein LMWP	VEGFR	Cancer
Protein LMWP is a cell-penetrating peptide with vascular endothelial growth factor (VEGF) inhibitory activity. Protein LMWP can inhibit tumor growth and is used in cancer research .

HY-13892

Dovitinib dilactic acid CHIR-258 dilactic acid; TKI258 dilactic acid	VEGFR	Cancer
Dovitinib (dilactic acid) is an orally active inhibitor of VEGF kinase. Dovitinib (dilactic acid) inhibits receptor tyrosine kinases (RTKs) involved in solid and hematologic cancers and tumor angiogenesis .

HY-151465

HIF-1α-IN-4	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-1α-IN-4 is a HIF-1α inhibitor with an IC₅₀ value of 24 nM (in HEK293T cell). HIF-1α-IN-4 downregulates VEGF and PDK1 mRNA expressions under hypoxia. HIF-1α-IN-4 can be used in the research of cancer .

HY-P5133

Synstatin (92-119) SSTN92-119	Integrin	Cancer
Synstatin (92-119) is an anti-tumor agent that inhibits angiogenesis and cancer cell invasion. Synstatin (92-119) down-regulates integrin α?β3 and reduces the activation of angiogenic growth factors VEGF and FGF-2 .

HY-115436

LYG-202	Apoptosis	Cancer
LYG-202, a flavonoid, has potent anti-angiogenic and antitumor activity. LYG-202 inhibits VEGF-stimulated HUVEC migration and tube formation. LYG-202 induces cancer cell apoptosis .

HY-135671

AhR modulator-1	Aryl Hydrocarbon Receptor VEGFR Estrogen Receptor/ERR	Endocrinology Cancer
AhR modulator-1 (compound 6-MCDF) is a selective and orally active aryl hydrocarbon receptor (AhR) modulator. AhR modulator-1 inhibits metastasis, in part, by inhibiting prostatic VEGF production prior to tumor formation. AhR modulator-1 also possess anti-estrogenic properties in rat uterus .

HY-P9951A

*Ranibizumab (anti-VEGF)* RG-6321 (anti-VEGF)	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-17369

Tirofiban hydrochloride monohydrate 1 Publications Verification L700462 hydrochloride monohydrate; MK383 hydrochloride monohydrate	Integrin	Cardiovascular Disease
Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369B

Tirofiban 1 Publications Verification L700462; MK383	Integrin	Cardiovascular Disease
Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369A

Tirofiban hydrochloride L700462 hydrochloride; MK383 hydrochloride	Integrin	Cardiovascular Disease
Tirofiban (L700462) hydrochloride is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-P99416

Abicipar pegol AGN-150998; MP0112	VEGFR	Cardiovascular Disease Inflammation/Immunology
Abicipar pegol (AGN-150998, MP0112) is an anti-VEGF DARPin molecule, a novel class of small proteins containing ankyrin repeat domains engineered to bind with high specificity and affinity to target proteins. Abicipar pegol effectively inhibits angiogenesis and vascular permeability and is used in the study of diseases related to ocular inflammation by intravitreal injection, reducing mean retinal thickness and leakage area .

HY-151466

HIF-1α-IN-5	HIF/HIF Prolyl-Hydroxylase Monoamine Oxidase	Cancer
HIF-1α-IN-5 is a HIF-1α inhibitor with an IC₅₀ value of 24 nM (in HEK293T cell). HIF-1α-IN-5 also inhibits MAO-A activity. HIF-1α-IN-5 downregulates VEGF and PDK1 mRNA expressions under hypoxia. HIF-1α-IN-5 can be used in the research of cancer .

HY-162011

GPR183 antagonist-2	EBI2/GPR183	Inflammation/Immunology
GPR183 antagonist-2 (compound 32) is a selective GPR183 antagonist with good water solubility and excellent pharmacokinetic properties. GPR183 antagonist-2 significantly reduces paw and joint swelling and gene expression of pro-inflammatory cytokines (MCP-1, MMPs, and VEGF) in a collagen-induced arthritis (CIA) mouse model in a dose-dependent manner. GPR183 antagonist-2 can be used in the study of autoimmune diseases .

HY-P9951

Ranibizumab RG-6321	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-B0223

Albendazole 3 Publications Verification SKF-62979	Parasite Microtubule/Tubulin Autophagy Apoptosis Reactive Oxygen Species VEGFR HIF/HIF Prolyl-Hydroxylase Antibiotic Bacterial	Infection Cancer
Albendazole (SKF-62979) is an orally active and broad-spectrum parasiticide with high effectiveness and low host toxicity, is used for the research of gastrointestinal parasites in humans and animals. Albendazole induces apoptosis and autophagy in cancer cells. Albendazole also inhibits tubulin polymerization and HIF-1α, *VEGF* expression, has antioxidant activity, and inhibits the glycolytic process in cancer cells .

HY-147712

PKC-IN-4	PKC	Inflammation/Immunology
PKC-IN-4 (compound 7l) is a potent and orally active aPKC inhibitor with an IC₅₀ of 0.52 µM. PKC-IN-4 inhibits TNF-α induced NF-κB activity in vitro. PKC-IN-4 blocks VEGF- and TNFα-induced permeability across the retinal vasculature .

HY-P99905

Efdamrofusp alfa	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-N2666

5α-Hydroxycostic acid	VEGFR	Cancer
5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating *VEGF/VEGFR2* and Ang2/Tie2 pathways .

HY-P99675

Ivonescimab

AK112
PD-1/PD-L1 VEGFR Cancer

Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research .

Ivonescimab AK112	PD-1/PD-L1 VEGFR	Cancer
Ivonescimab (AK112) is a *PD-1/VEGF* Bispecific Antibody. Ivonescimab can be used for cancer research .

HY-P9920

Ramucirumab 2 Publications Verification	VEGFR	Cancer
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab is also an angiogenesis inhibitor .

HY-P99215

Parsatuzumab Anti-EGFL7; RG 7414	VEGFR	Cancer
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .

HY-108801

Aflibercept VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-108801A

*Aflibercept (VEGF* Trap)**	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-P9920A

Ramucirumab (anti-VEGFR)	VEGFR	Cancer
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .

HY-147762

NRP1 antagonist 2

Complement System Cancer

NRP1 antagonist 2 (Compound 1) is an NRP1 antagonist .

NRP1 antagonist 2	Complement System	Cancer
NRP1 antagonist 2 (Compound 1) is an NRP1 antagonist .

HY-153484A

Bevasiranib sodium	VEGFR Small Interfering RNA (siRNA)	Others
Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).

HY-153484

Bevasiranib	VEGFR Small Interfering RNA (siRNA)	Others
Bevasiranib is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).

HY-137941

Roxatidine	Histamine Receptor	Inflammation/Immunology
Roxatidine is an active metabolite of Roxatidine acetate hydrochloride, is a histamine H2-receptor antagonist. Roxatidine, an anti-ulcer agent, suppresses histamine release (thus inhibiting proton secretion) and inhibits the production of VEGF-1, an important marker of inflammation and angiogenesis. Anti-allergic inflammatory effect .

HY-B0164

Mizolastine	Histamine Receptor	Inflammation/Immunology
Mizolastine is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine effectively inhibits mRNA expression of *VEGF165, VEGF120, TNF-α* and KC. Mizolastine can be used in studies of allergic rhinitis and chronic idiopathic urticarial .

HY-B0164A

Mizolastine dihydrochloride	Histamine Receptor	Inflammation/Immunology
Mizolastine dihydrochloride is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine dihydrochloride effectively inhibits mRNA expression of *VEGF165, VEGF120, TNF-α* and KC. Mizolastine dihydrochloride can be used in studies of allergic rhinitis and chronic idiopathic urticarial .

HY-112547

CRT5 CRT0066051	PKD	Others
CRT5, a pyrazine benzamide, is a potent and selective inhibitor for all three isoforms of PKD in endothelial cells treated with VEGF (IC₅₀s = 1, 2, and 1.5 nM for PKD1, PKD2, and PKD3, respectively). CRT5 decreases VEGF-induced endothelial migration, proliferation and tubulogenesis .

HY-P9906

Bevacizumab Maximum Cited Publications 23 Publications Verification Anti-Human VEGF, Humanized Antibody	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all *VEGF-A* isoforms with high affinity.

HY-P990082

Suvemcitug

VEGFR Cancer

Suvemcitug is a humanized IgG1κ antibody targeting VEGF derived from the African hare (Oryctolagus cuniculus) .

Suvemcitug	VEGFR	Cancer
Suvemcitug is a humanized IgG1κ antibody targeting *VEGF* derived from the African hare (Oryctolagus cuniculus) .

HY-P4253

Arginyl-Glutamine	VEGFR	Cardiovascular Disease
Arginyl-Glutamine is a dipeptide that can decrease *VEGF* levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy .

HY-110066

(Z)-Guggulsterone 2 Publications Verification	Apoptosis VEGFR Akt Angiotensin-converting Enzyme (ACE) SARS-CoV FXR	Cancer
(Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the *VEGF–VEGF-R2–Akt* signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection .

HY-P99116

Faricimab RG7716	VEGFR	Metabolic Disease
Faricimab is a bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A). Faricimab can be used for diabetic macular edema (DME) research .

HY-116624

MAZ51 2 Publications Verification	VEGFR Apoptosis	Cancer
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4) tyrosine kinase. MAZ51 inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2. MAZ51 had no effect on ligand-induced autophosphorylation of EGFR, IGF-1R and PDGFRβ. MAZ51 blocks proliferation and induces apoptosis in a wide variety of tumor cells. Antitumor activity .

HY-139822

VEGFR-2-IN-10

VEGFR Cancer

VEGFR-2-IN-10 exhibits increased antiangiogenic potency (IC₅₀ = 0.7 μM) against VEGF-induced VEGFR2 phosphorylation without cytotoxic effects.

VEGFR-2-IN-10	VEGFR	Cancer
VEGFR-2-IN-10 exhibits increased antiangiogenic potency (IC₅₀ = 0.7 μM) against VEGF-induced VEGFR2 phosphorylation without cytotoxic effects.

HY-N0545

Taurocholic acid sodium 5+ Cited Publications Sodium taurocholate; N-Choloyltaurine sodium	VEGFR Endogenous Metabolite	Inflammation/Immunology
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-B0239

Chloramphenicol 5+ Cited Publications	Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase VEGFR Autophagy Apoptosis Beclin1 JNK Akt MMP	Infection Cancer
Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .

HY-N0135

Tanshinone IIA 10+ Cited Publications Dan Shen ketone	VEGFR	Cardiovascular Disease Cancer
Tanshinone IIA (Tan IIA) is one of the main compositions in the root of Salvia miltiorrhiza Bunge. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2*.

HY-B1788

Taurocholic acid 5+ Cited Publications N-Choloyltaurine
Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-P9973

Brolucizumab DLX1008; ESBA 1008; RTH258	VEGFR	Cancer
Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (K_D=1.05 pM). Brolucizumab can be used for the research of cancer .

HY-104075

R916562	TAM Receptor VEGFR	Cancer
R916562 is an orally active and selective *Axl/VEGF-R2* inhibitor with IC₅₀s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis .

Cat. No.	Product Name

HY-L125

Anti-Pulmonary Fibrosis Compound Library

1676 compounds

Pulmonary fibrosis (PF), also known as diffuse interstitial pulmonary fibrosis, is a very common end-stage manifestation of several diseases, including idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and scleroderma, characterised by excessive matrix deposition and destruction of the lung architecture, finally leading to respiratory insufficiency. PF has become a global disease with significantly increased incidence rate, and the most common form of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).

Lung fibrosis is a complex disease, a multitude of signal factors and signaling pathways is disrupted in this complex disease, such as TGF-β, Wnt, VEGF and PI3K–Akt. MCE offers a unique collection of 1676 compounds with identified and potential anti-pulmonary fibrosis activity. MCE Anti-Pulmonary Fibrosis Compound Library is a useful tool for anti-pulmonary fibrosis drugs screening and other related research.

HY-L088

1984 compounds

Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer).

MCE offers a unique collection of 1984 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.

HY-L103

Anti-Colorectal Cancer Compound Library

1618 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1618 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area

HY-P5558

KLTWQELYQLKYKGI	VEGFR	Inflammation/Immunology
KLTWQELYQLKYKGI (QK) is a VEGF mimicking peptide, binds to the VEGF receptors and competes with VEGF. KLTWQELYQLKYKGI is active in gastric ulcer healing in rodents when administered either orally or systemically. KLTWQELYQLKYKGI shows the ability to induce capillary formation and organization in vitro .

HY-P5133

Synstatin (92-119) SSTN92-119	Integrin	Cancer
Synstatin (92-119) is an anti-tumor agent that inhibits angiogenesis and cancer cell invasion. Synstatin (92-119) down-regulates integrin α?β3 and reduces the activation of angiogenic growth factors VEGF and FGF-2 .

HY-P1663

ATWLPPR Peptide 1 Publications Verification	Peptides	Others
ATWLPPR Peptide is a biological active peptide. (This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo.)

HY-P5107

Protein LMWP	VEGFR	Cancer
Protein LMWP is a cell-penetrating peptide with vascular endothelial growth factor (VEGF) inhibitory activity. Protein LMWP can inhibit tumor growth and is used in cancer research .

HY-P4253

Arginyl-Glutamine	VEGFR	Cardiovascular Disease
Arginyl-Glutamine is a dipeptide that can decrease *VEGF* levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy .

HY-P5438

Srctide	Peptides	Others
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)

HY-P5527F

FAM-CSKtide	Peptides	Others
FAM-CSKtide is a biological active peptide. (This is a FAM labeled peptide substrate (Abs/Em = 494/521 nm) for C-terminal Src kinase (Csk) and many other kinases such as Axl, cKit, ERBB4, Fes, Flt3, IGF-1 R, MET, MUSK, PYK2, Ret, TIE2, TrkA, VEGF-R1 and VEGF-R2.)

HY-P3999

Fibulostatin 6.2

Peptides Cardiovascular Disease

Fibulostatin 6.2 is an anti-angiogenic peptide that can inhibit migration of human umbilical vein endothelial cells in vitro .

HY-P3995

Scospondistatin	Peptides	Cardiovascular Disease
Scospondistatin is an anti-angiogenic peptide that can inhibit proliferation and migration of human umbilical vein endothelial cells in vitro .

HY-13718

Oglufanide H-Glu-Trp-OH; L-Glutamyl-L-tryptophan	VEGFR HCV Endogenous Metabolite	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascular endothelial growth factor (VEGF). Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities .

HY-P1435A

NoxA1ds TFA	NADPH Oxidase	Cancer
NoxA1ds TFA is a potent and selective NADPH oxidase 1 (NOX1) inhibitor (IC₅₀=20 nM). NoxA1ds TFA exhibits selectivity for NOX1 over NOX2, NOX4, NOX5 and xanthine oxidase. NoxA1ds TFA inhibits NOX1-derived O2- production in HT-29 human colon cancer cells. NoxA1ds TFA attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro.

HY-16050

Plitidepsin 2 Publications Verification Aplidine; PM90001	DNA/RNA Synthesis SARS-CoV	Infection Cancer
Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( K_D=80 nM) . Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC₉₀ of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research .

HY-P2813

Hirudin	Thrombin Apoptosis	Cardiovascular Disease Cancer
Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .

Cat. No.	Product Name	Target	Research Area

HY-P9906A

Bevacizumab (PBS) Maximum Cited Publications 23 Publications Verification Anti-Human VEGF, Humanized Antibody (PBS)	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all *VEGF-A* isoforms with high affinity .

HY-P9951A

*Ranibizumab (anti-VEGF)* RG-6321 (anti-VEGF)	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-P9951

Ranibizumab RG-6321	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-P99416

Abicipar pegol AGN-150998; MP0112	VEGFR	Cardiovascular Disease Inflammation/Immunology
Abicipar pegol (AGN-150998, MP0112) is an anti-VEGF DARPin molecule, a novel class of small proteins containing ankyrin repeat domains engineered to bind with high specificity and affinity to target proteins. Abicipar pegol effectively inhibits angiogenesis and vascular permeability and is used in the study of diseases related to ocular inflammation by intravitreal injection, reducing mean retinal thickness and leakage area .

HY-P99905

Efdamrofusp alfa	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-P99675

Ivonescimab

AK112
PD-1/PD-L1 VEGFR Cancer

Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research .

HY-P9920

Ramucirumab 2 Publications Verification	VEGFR	Cancer
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab is also an angiogenesis inhibitor .

HY-P990148

*Anti-Mouse VEGF-A Antibody (2G11-2A05)*	Inhibitory Antibodies	Others
Anti-Mouse VEGF-A Antibody (2G11-2A05) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse VEGF-A.

HY-P99215

Parsatuzumab Anti-EGFL7; RG 7414	VEGFR	Cancer
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .

HY-108801

Aflibercept VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-108801A

*Aflibercept (VEGF* Trap)**	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-P9920A

Ramucirumab (anti-VEGFR)	VEGFR	Cancer
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .

HY-P9906

Bevacizumab Maximum Cited Publications 23 Publications Verification Anti-Human VEGF, Humanized Antibody	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all *VEGF-A* isoforms with high affinity.

HY-P990082

Suvemcitug

VEGFR Cancer

Suvemcitug is a humanized IgG1κ antibody targeting VEGF derived from the African hare (Oryctolagus cuniculus) .

HY-P99116

Faricimab RG7716	VEGFR	Metabolic Disease
Faricimab is a bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A). Faricimab can be used for diabetic macular edema (DME) research .

HY-P9973

Brolucizumab DLX1008; ESBA 1008; RTH258	VEGFR	Cancer
Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (K_D=1.05 pM). Brolucizumab can be used for the research of cancer .

HY-P99852

Dilpacimab ABT165; PR1283233	VEGFR	Cancer
Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and *VEGF* pathways.. Dilpacimab can be used in research of cancer .

HY-P99330

Vanucizumab Anti-Human VEGFA Recombinant Antibody; RO5520985	VEGFR Tie	Cancer
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks *VEGF-A* and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .

HY-P99768

Olinvacimab TTAC-0001	VEGFR	Cancer
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a K_d value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .

HY-145633

Sozinibercept OPT 302; VGX-300	VEGFR	Cardiovascular Disease
Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of *VEGF-C/D*, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats .

HY-P99377

Navicixizumab OMP-305B83; Anti-DLL4 Reference Antibody (navicixizumab)	Notch	Cancer
Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer .

HY-108798

Ziv-aflibercept	VEGFR	Cardiovascular Disease Cancer
Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases .

HY-P99590

Sotatercept ACE-011	TGF-β Receptor	Inflammation/Immunology Cancer
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2666

5α-Hydroxycostic acid	Other Terpenoids Classification of Application Fields Terpenoids Source classification Erythrina burttii Baker f. Plants Compositae Disease Research Fields Cancer	VEGFR
5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating *VEGF/VEGFR2* and Ang2/Tie2 pathways .

HY-110066

(Z)-Guggulsterone 2 Publications Verification	Classification of Application Fields Commiphora myrrha (Nees) Engl. Source classification Plants Burseraceae Disease Research Fields Steroids Cancer	Apoptosis VEGFR Akt Angiotensin-converting Enzyme (ACE) SARS-CoV FXR
(Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the *VEGF–VEGF-R2–Akt* signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection .

HY-N0545

Taurocholic acid sodium 5+ Cited Publications Sodium taurocholate; N-Choloyltaurine sodium	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids	VEGFR Endogenous Metabolite
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-B0239

Chloramphenicol 5+ Cited Publications	Structural Classification Classification of Application Fields Anti-aging Source classification Antibacterial Disease Research Endogenous metabolite Other Antibiotics Infection Human Gut Microbiota Metabolites Plant Cell Culture Microorganisms Antibiotics Resistance Selection Animal Husbandry Anticancer Disease Research Fields Cancer	Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase VEGFR Autophagy Apoptosis Beclin1 JNK Akt MMP
Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .

HY-N7177

Hydroxytanshinone IIA	Quinones Classification of Application Fields Labiatae Source classification Samanea saman (Jacq.) Merr. Plants Naphthalene Quinones Disease Research Fields Cancer	Drug Metabolite VEGFR
Hydroxytanshinone IIA is a hydroxylated metabolite of Tanshinone IIA. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2* .

HY-N0135

Tanshinone IIA Maximum Cited Publications 15 Publications Verification Dan Shen ketone	Quinones Structural Classification Classification of Application Fields Terpenoids Labiatae Source classification Samanea saman (Jacq.) Merr. Diterpenoids Plants Naphthalene Quinones Disease Research Fields Cancer	VEGFR
Tanshinone IIA (Tan IIA) is one of the main compositions in the root of Salvia miltiorrhiza Bunge. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2*.

HY-12686

5Z-7-Oxozeaenol 5+ Cited Publications FR148083; L783279; LL-Z 1640-2	Structural Classification Natural Products Monophenols Microorganisms Classification of Application Fields Source classification Phenols Inflammation/Immunology Disease Research Fields	MAP3K VEGFR Antibiotic
5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and *VEGF-R2, with IC₅₀*s of 8 nM and 52 nM, respectively.

HY-126114

Lupeol acetate 1 Publications Verification	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Umbelliferae Inflammation/Immunology Disease Research Fields Carphephorus corymbosus (Nutt.) Torr. & A.Gray	COX Interleukin Related
Lupeol acetate, a derivative of Lupeol, suppresses the progression of rheumatoid arthritis (RA) by inhibiting the activation of macrophages and osteoclastogenesis through downregulations of TNF-α, IL-1β, MCP-1, COX-2, VEGF and granzyme B .

HY-N0896

Inulicin 1 Publications Verification 1-O-Acetylbritannilactone	Phyllodium pulchellum (L.) Desv. Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Compositae Inflammation/Immunology Disease Research Fields	NF-κB COX
Inulicin (1-O-Acetylbritannilactone) is an active compound that inhibits VEGF-mediated activation of Src and FAK. Inulicin (1-O-Acetylbritannilactone) inhibits LPS-induced PGE₂ production and COX-2 expression, and NF-κB activation and translocation.

HY-N0545R

Taurocholic acid sodium (Standard) Sodium taurocholate (Standard); N-Choloyltaurine sodium (Standard)	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids	VEGFR Endogenous Metabolite
Taurocholic acid (sodium) (Standard) is the analytical standard of Taurocholic acid (sodium). This product is intended for research and analytical applications. Taurocholic acid sodium (Sodium taurocholate; N-Choloyltaurine sodium) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Immunoregulation effect .

HY-119767

Jolkinolide A	Structural Classification Euphorbia fischeriana Steud. Terpenoids Source classification Diterpenoids Euphorbiaceae Plants	VEGFR Apoptosis
Jolkinolide A is a diterpenoid, can be extracted from the roots of Euphorbia fischeriana Steud. Jolkinolide A exhibits anti-tumor activity, by affecting on angiogenesis of tumor tissues. Jolkinolide A significantly inhibits the Akt-STAT3-mTOR signaling pathway and reduces the expression of *VEGF* in A549 cells .

HY-13718

Oglufanide H-Glu-Trp-OH; L-Glutamyl-L-tryptophan	Cardiovascular Disease Structural Classification Classification of Application Fields Animals Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	VEGFR HCV Endogenous Metabolite
Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascular endothelial growth factor (VEGF). Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities .

HY-114535

Jaceidin	Flavonoids Erythrina suberosa Roxb. Source classification Plants Compositae Isoflavones	EGFR
Jaceidin is a promising lead molecule for potent VEGFR inhibitor with excellent membrane permeability and oral bioavailability. Jaceidin exhibits anti-tumor activities .

HY-N5136

25(R,S)-Ruscogenin	Liliaceae Microorganisms Classification of Application Fields Source classification Liriope platyphylla Wang et Tang Plants Disease Research Fields Steroids Cancer	Apoptosis PI3K Akt mTOR
Ruscogenin suppresses HCC metastasis by reducing the expression of MMP-2, MMP-9, uPA, VEGF and HIF-1α via regulating the PI3K/Akt/mTOR signaling pathway . And Ruscogenin alleviates LPS-induced pulmonary endothelial cell apoptosis by su

HY-N5112B

β,β-Dimethylacrylshikonin 1 Publications Verification Isoarnebin I	Quinones Structural Classification Classification of Application Fields Source classification Phenols Polyphenols Plants Lithospermum erythrorhizon Sieb. et Zucc. Naphthalene Quinones Disease Research Fields Boraginaceae Cancer	HIF/HIF Prolyl-Hydroxylase
β,β-Dimethylacrylshikonin (Isoarnebin I) is a naphthoquinone derivative isolated from Lithospermum erythrorhizon Sieb. et Zucc. , promotes angiogenesis by inducing eNOS, VEGF and HIF-1α expression through the PI3K-dependent pathway.β,β-Dimethylacrylshikonin has anti-tumor activity .

HY-N7830

7α,15-Dihydroxydehydroabietic acid	Structural Classification Terpenoids Labiatae Source classification Diterpenoids Plants Achillea clypeolata Sm.	ERK
7α,15-Dihydroxydehydroabietic acid is a natural abietane-type diterpenoid with antiangiogenic effects .

HY-134000

Emodic acid NSC624610	Quinones Structural Classification Human Gut Microbiota Metabolites Microorganisms Leguminosae Cercis chinensis Bunge Anthraquinones Source classification Plants Endogenous metabolite	p38 MAPK NF-κB ERK JNK VEGFR MMP
Emodic acid (NSC624610) is an anthraquinone compound isolated from A. microcarpus, which can inhibit the proliferation of cancer cells by inhibiting the activity of NF-κB. Emodic acid can also inhibit the phosphorylation of p38, ERK and JNK, the secretion of tumor-promoting cytokines IL-1β and IL-6, and the expression of *VEGF* and MMP, thereby inhibiting the invasion and migration potential of cancer cells .

HY-B2163

Astaxanthin 5 Publications Verification	Cardiovascular Disease Structural Classification Classification of Application Fields Anti-aging Source classification Whitening Agent Research on Agricultural Breeding Food Research Agricultural Research Microorganisms Sunscreen Terpenoids Pigments Diterpenoids Cosmetic Research Disease Research Fields	PPAR Reactive Oxygen Species STAT NF-κB Apoptosis
Astaxanthin, the red dietary carotenoid, is an orally effective and potent antioxidant. Astaxanthin inhibits NF-κB and down-regulates *VEGF* in blood glucose. Astaxanthin exerts anti-cancer cell proliferation, increases apoptosis, impairs migration and invasion by activating PPARγ and reducing the expression of STAT3. Astaxanthin also has neuroprotective and anti-inflammatory activity and can be used in studies of cancer, diabetic retinopathy, cardiovascular disease, and in the coloring of animal feed .

HY-N10330

7-Hydroxyneolamellarin A	Structural Classification Animals Source classification Phenols	HIF/HIF Prolyl-Hydroxylase VEGFR
7-Hydroxyneolamellarin A is a natural product that could be derived from sponge Dendrilla nigra. 7-Hydroxyneolamellarin A is a potent hypoxia-inducible factor-1α (HIF-1α) inhibitor. 7-Hydroxyneolamellarin A attenuates the accumulation of hypoxia-inducible factor-1α (HIF-1α) protein and inhibits vascular epidermal growth factor (VEGF) transcriptional activity. 7-Hydroxyneolamellarin A can be used in research of cancer .

HY-16050

Plitidepsin 2 Publications Verification Aplidine; PM90001	Structural Classification Microorganisms Marine natural products Source classification Other marine organisms	DNA/RNA Synthesis SARS-CoV
Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( K_D=80 nM) . Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC₉₀ of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research .

Cat. No.	Product Name	Chemical Structure

HY-B0239S2

Threo-Chloramphenicol-d6

Threo-Chloramphenicol-d₆ is the deuterium labeled Chloramphenicol[1]. Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research[2][3][4].

HY-121356S1

Carebastine-d5 Methyl Ester
Carebastine-d₅ Methyl Ester is the deuterium labeled Carebastine. Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner[1]. Carebastine suppresses the expression of macrophage migration inhibitory factor[2].

HY-121356S

Carebastine-d5
Carebastine-d₅ is the deuterium labeled Carebastine. Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner[1]. Carebastine suppresses the expression of macrophage migration inhibitory factor[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks